Viking’s Phase IIb NASH Data Provide Across-The-Board Success

 
• By Joseph Haas

Competing with Madrigal in the THRβ agonist class in non-alcoholic steatohepatitis, Viking’s VK2809 reports stronger efficacy and better safety and tolerability than resmetirom at that stage.

Archer
Viking's NASH candidate hits multiple targets in Phase IIb study • Source: Shutterstock

More from Clinical Trials

More from R&D